Novo Nordisk Expects Sales Decline in 2026 Despite Strong 2025 Results

Novo Nordisk, the maker of popular diabetes and weight-loss drugs Ozempic and Wegovy, reported strong results for 2025 with a 10% increase in sales and a 6% rise in operating profit. These results were better than what most analysts had expected.

However, the company announced it expects sales to decline in 2026. Novo Nordisk forecasts sales to fall between 5% and 13% at constant exchange rates, which is a sharp change from the growth seen last year.

Following this announcement, Novo Nordisk's American depositary shares dropped by 11%. The company said part of the reason for the expected decline is lower sales in the United States.

The stock fell because the company predicted its sales would decline in 2026, which worried investors.

In 2025, the company’s sales increased by 10% and operating profit grew by 6%, exceeding most expectations.

Novo Nordisk expects a decline mainly due to lower sales in the United States.

GlobeNewsWire

In 2025, Novo Nordisk's sales increased by 10% and operating profit increased by 6%, compared to previously issued guidance of 8 to 11% sales growth and

CNBC

Novo Nordisk said late Tuesday it sees sales and profit growth declining this year, expecting a U.S. sales hit. Novo's American depositary shares fell 11% on the news.

Barrons

The Ozempic and Wegovy maker reports full-year sales of 309.1 billion Danish krone, beating analysts' forecasts.

Reuters

Wegovy maker Novo Nordisk expects a decline in sales this year, it said on Tuesday as it reported fourth-quarter operating profit slightly above forecasts.

WSJ

The Danish drugmaker said adjusted sales should decline between 5% and 13% at constant exchange rates in 2026, a reversal from last year, when sales grew 10%.

Proactive Investors

Novo Nordisk (NYSE:NVO) shares fell almost 13% on Tuesday as the Danish drugmaker forecast lower sales and profit growth for 2026, citing reduced prices in the United States and loss of exclusivity for its blockbuster GLP-1 drugs Wegovy and Ozempic in several markets. For 2026, Novo Nordisk expects...

Market Watch

The maker of Ozempic and Wegovy blamed pricing pressures and competition for its downbeat outlook.

Invezz

Novo Nordisk stock (NVO) plunged approximately 15% after the Danish pharmaceutical giant posted better-than-expected 2025 results but delivered a weak 2026 outlook. The company reported full-year 2025 sales growth of 10% at constant exchange rates, remaining within its prior guidance range of 8-11%,...

Investors Business Daily

Novo Nordisk stock crashed Tuesday after the company said it expects sales and operating profit to decline by 5% to 13% this year.

Benzinga

Novo Nordisk A/S (NYSE: NVO) stock is trading lower on Tuesday after the weight-loss drug maker released its 2026 full-year sales and operating profit outlook.

Bloomberg Markets and Finance

Novo Nordisk CEO Mike Doustdar discusses the company's updated 2026 sales guidance, forecasting a decline of 5 to 13% at constant exchange rates. Doustdar highlights the strong uptake of Novo Nordisk's oral GLP-1 treatment Wegovy, which has reached over 170,000 patients within four weeks of launch.

Reuters

Shares of obesity drugmakers and developers slid on Tuesday after Novo Nordisk forecast a sharper-than-expected sales decline for 2026, underscoring intensifying competition in the blockbuster weight-loss market.

Seeking Alpha

Novo Nordisk A/S faces a structural margin crisis as oral Wegovy cannibalizes its high-margin injectable business. NVO Q4 2025 results confirm margin contraction: net margin fell 170 bps to 33.1%, with operating profit down 1% despite 6% sales growth. 2026 guidance forecasts adjusted NVO sales and E...

The Motley Fool

Expand NYSE: NVO Novo Nordisk Today's Change (-14.75%) $-8.69 Current Price $50.24 Key Data Points Market Cap $199B Day's Range $49.96 - $58.63 52wk Range $43.08 - $93.80 Volume 3.7M Avg Vol 21M Gross Margin 81.93% Dividend Yield 2.93% Novo Nordisk (NVO 14.75%), a diabetes and obesity drug maker, cl...

Reuters

Swiss drugmaker Novartis forecast a decline in 2026 operating profit in the low single-digit percentage range on Wednesday, held back by competition from cheaper copies of established products such as heart drug Entresto.

WSJ

The pharma major said it had strong results in 2025, but guided toward a decline in core operating profit this year.

GlobeNewsWire

Bagsværd, Denmark, 4 February 2026 – Today, Novo Nordisk A/S has issued its 2025 annual report. The report is available here: https://www.novonordisk.com/investors/annual-report.html and is attached in iXBRL format.

Reuters

Danish obesity drug giant Novo Nordisk is set to be punished by investors on Wednesday after it gave a far bleaker-than-expected outlook for 2026 and flagged a tough weight-loss market battle ahead as prices come under pressure.

CNBC

"People should expect that it goes down before it comes back up," CEO Mike Doustdar told CNBC's "Early Edition Europe" on Wednesday. In this article NVO

CNBC International TV

Novo Nordisk CEO Mike Doustdar discusses the pharma giant's Q4 reporting, uptake of obesity drugs and how he plans to navigate price pressures throughout 2026.

WSJ

The stock tumbled 19% at the opening bell in Copenhagen after its outlook for the year ahead disappointed investors.

CNBC International TV

Novo Nordisk CEO Mike Doustdar warns things will get worse before they get better for the obesity drugmaker after it issued disappointing guidance, causing its stock to tumble. 🔗Read more: cnb.cx/3M4Teu2

Market Watch

Having pre-announced earnings a day earlier, Novo Nordisk CEO Mike Doustdar, faced the European media Wednesday morning and gave a series of downbeat assessments of the company's prospects in 2026.

Reuters

European shares edged lower on Wednesday, as shares of Novo Nordisk slumped after the weight-loss drugmaker issued a bleak forecast, while investors tracked software shares and awaited a key inflation report.

Reuters

Novo Nordisk shares tumbled 16% on Wednesday, wiping off around $50 billion from the Wegovy maker's market capitalization after it warned on Tuesday its sales and profits would fall in 2026.

Reuters

Danish obesity drug maker Novo Nordisk's new CEO risks being on the losing side of a damaging price war as "unprecedented" price pressure forces it to slash the cost of its blockbuster Wegovy drug in the United States, analysts and investors said.

GlobeNewsWire

Bagsværd, Denmark, 4 February 2026 – Novo Nordisk A/S has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2025. The reports are available at the SEC's we...